Adcock Says $1.3 Billion Acquisition Talks Remain Exclusive To CFR
This article was originally published in PharmAsia News
Adcock Ingram indicated it expects to reach an agreement with Chile's CFR Pharmaceuticals to take over the South Africa drug maker, with the financial talk now at $1.3 billion.
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.